- Home
- BGH vs ABEO Comparison
BGH vs ABEO Comparison
Compare BGH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGH | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | BGH | ABEO |
|---|---|---|
| Price | $15.08 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 61.5K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | ★ N/A | $4.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.92 | $3.93 |
| 52 Week High | $14.50 | $7.54 |
Technical Indicators
Market Signals| Indicator | BGH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 57.89 |
| Support Level | $15.02 | $4.53 |
| Resistance Level | $15.25 | $4.92 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 74.58 | 85.71 |
Price Performance
Historical ComparisonAbout BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.